CERo Therapeutics Holdings ( ($CERO) ) has shared an update. On December 19, 2025, CERo Therapeutics Holdings, Inc. held a Special Meeting of ...

Under those agreements, Cero Therapeutics had issued and sold a total of 112,273 shares of common stock to the investor for aggregate proceeds of approximately $7.5 million as of June 30, 2025. The ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

1 Day CERO 0.57% DJIA -0.45% Russell 2K -0.09% Health Care/Life Sciences -0.36% ...

Fintel reports that on May 19, 2025, Maxim Group initiated coverage of CERo Therapeutics Holdings (NasdaqCM:CERO) with a Buy recommendation. As of May 7, 2025, the average one-year price target for ...

The stock's current price of $0.07 is trading near its 52-week low, with InvestingPro data showing that CERO is just 0.59% of its 52-week high. This steep decline is further illustrated by the stock's ...

Cero Therapeutics Holdings, Inc. (NASDAQ:CERO), a biotech firm specializing in biological products, is confronting the possibility of delisting from The Nasdaq Global Market due to non-compliance with ...

CERo Therapeutics Holdings, Inc. has announced that TriStar Centennial Medical Center in Nashville, Tennessee, will serve as a clinical trial site for its Phase 1 clinical study of CER-1236, a new ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.